CNTB
Connect Biopharma Holdings Ltd
NASDAQ · Healthcare · Biotechnology · CN
$1.28
−0.78%Sep 15, 2026, 15:46 UTC
Connect Biopharma Holdings Limited released topline results from its global Phase 2 study evaluating rademikibart, sending its stock to a 52-week low on Tuesday.
Source:Aug 12, 2026, 20:05 UTC
Connect Biopharma Holdings Limited reported financial results for the second quarter of 2026, ending June 30, 2026.
Source:Jul 23, 2026, 06:15 UTC
Connect Biopharma raised net proceeds of $18.6 million in a private placement in the first quarter of 2026.
Source:Jun 17, 2026, 13:00 UTC
Connect Biopharma completed enrollment in its Phase 2 Seabreeze STAT Asthma study evaluating rademikibart for acute asthma exacerbations.
Source: